Jurors awarded $2.54 billion to a unit of Merck & Co. last week in a suit alleging its patented compound was used by Gilead Sciences Inc. to make the hepatitis C drugs Sovaldi and Harvoni.
Jurors upheld the patent on behalf of Merck’s Idenix unit and found the infringement was willful, report
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
BusinessDay
Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more
